Utilization of and Adherence to Guideline-Recommended Lipid-Lowering Therapy After Acute Coronary Syndrome: Opportunities for Improvement

Benjamin J. Hirsh; Nathaniel R. Smilowitz; Robert S. Rosenson; Valentin Fuster; Laurence S. Sperling

doi:10.1016/j.jacc.2015.05.030

Utilization of and Adherence to Guideline-Recommended Lipid-Lowering Therapy After Acute Coronary Syndrome: Opportunities for Improvement

Benjamin J. Hirsh
, Nathaniel R. Smilowitz
, Robert S. Rosenson
, Valentin Fuster
, Laurence S. Sperling

Research output: Contribution to journal › Review article › peer-review

106 Scopus citations

Abstract

In addition to aggressive lifestyle and nonlipid risk factor modification, statin therapy improves cardiovascular disease outcomes following acute coronary syndromes. Despite established benefits of treatment, contemporary registries reveal substantial underutilization of and nonadherence to statin therapy for secondary prevention. In randomized controlled trials investigating statin therapy, including moderate-intensity statin plus ezetimibe therapy, rates of nonadherence are reported in up to 40% of subjects. Durable strategies to address gaps in lipid lowering for secondary prevention are essential to maximize reduction in cardiovascular disease risk.

Original language	English
Article number	21374
Pages (from-to)	184-192
Number of pages	9
Journal	Journal of the American College of Cardiology
Volume	66
Issue number	2
DOIs	https://doi.org/10.1016/j.jacc.2015.05.030
State	Published - 14 Jul 2015

Keywords

adherence
ezetimibe
low-density lipoprotein cholesterol
secondary prevention
statin therapy

Access to Document

10.1016/j.jacc.2015.05.030

Cite this

@article{feab4ec82f314f7ea7613e8499dca6d1,

title = "Utilization of and Adherence to Guideline-Recommended Lipid-Lowering Therapy After Acute Coronary Syndrome: Opportunities for Improvement",

abstract = "In addition to aggressive lifestyle and nonlipid risk factor modification, statin therapy improves cardiovascular disease outcomes following acute coronary syndromes. Despite established benefits of treatment, contemporary registries reveal substantial underutilization of and nonadherence to statin therapy for secondary prevention. In randomized controlled trials investigating statin therapy, including moderate-intensity statin plus ezetimibe therapy, rates of nonadherence are reported in up to 40\% of subjects. Durable strategies to address gaps in lipid lowering for secondary prevention are essential to maximize reduction in cardiovascular disease risk.",

keywords = "adherence, ezetimibe, low-density lipoprotein cholesterol, secondary prevention, statin therapy",

author = "Hirsh, \{Benjamin J.\} and Smilowitz, \{Nathaniel R.\} and Rosenson, \{Robert S.\} and Valentin Fuster and Sperling, \{Laurence S.\}",

note = "Publisher Copyright: {\textcopyright} 2015 American College of Cardiology Foundation.",

year = "2015",

month = jul,

day = "14",

doi = "10.1016/j.jacc.2015.05.030",

language = "English",

volume = "66",

pages = "184--192",

journal = "Journal of the American College of Cardiology",

issn = "0735-1097",

publisher = "Elsevier Inc.",

number = "2",

}

Utilization of and Adherence to Guideline-Recommended Lipid-Lowering Therapy After Acute Coronary Syndrome: Opportunities for Improvement. / Hirsh, Benjamin J.; Smilowitz, Nathaniel R.; Rosenson, Robert S. et al.
In: Journal of the American College of Cardiology, Vol. 66, No. 2, 21374, 14.07.2015, p. 184-192.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - Utilization of and Adherence to Guideline-Recommended Lipid-Lowering Therapy After Acute Coronary Syndrome

T2 - Opportunities for Improvement

AU - Hirsh, Benjamin J.

AU - Smilowitz, Nathaniel R.

AU - Rosenson, Robert S.

AU - Fuster, Valentin

AU - Sperling, Laurence S.

PY - 2015/7/14

Y1 - 2015/7/14

N2 - In addition to aggressive lifestyle and nonlipid risk factor modification, statin therapy improves cardiovascular disease outcomes following acute coronary syndromes. Despite established benefits of treatment, contemporary registries reveal substantial underutilization of and nonadherence to statin therapy for secondary prevention. In randomized controlled trials investigating statin therapy, including moderate-intensity statin plus ezetimibe therapy, rates of nonadherence are reported in up to 40% of subjects. Durable strategies to address gaps in lipid lowering for secondary prevention are essential to maximize reduction in cardiovascular disease risk.

AB - In addition to aggressive lifestyle and nonlipid risk factor modification, statin therapy improves cardiovascular disease outcomes following acute coronary syndromes. Despite established benefits of treatment, contemporary registries reveal substantial underutilization of and nonadherence to statin therapy for secondary prevention. In randomized controlled trials investigating statin therapy, including moderate-intensity statin plus ezetimibe therapy, rates of nonadherence are reported in up to 40% of subjects. Durable strategies to address gaps in lipid lowering for secondary prevention are essential to maximize reduction in cardiovascular disease risk.

KW - adherence

KW - ezetimibe

KW - low-density lipoprotein cholesterol

KW - secondary prevention

KW - statin therapy

UR - https://www.scopus.com/pages/publications/84942417740

U2 - 10.1016/j.jacc.2015.05.030

DO - 10.1016/j.jacc.2015.05.030

M3 - Review article

C2 - 26160634

AN - SCOPUS:84942417740

SN - 0735-1097

VL - 66

SP - 184

EP - 192

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 2

M1 - 21374

ER -

Utilization of and Adherence to Guideline-Recommended Lipid-Lowering Therapy After Acute Coronary Syndrome: Opportunities for Improvement

Abstract

Keywords

Access to Document

Fingerprint

Cite this